Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Boston Scientific stock heads toward an October 28 outlook reset in 2026

Data breach Guidance lowered Operational disruption AI-generated analysis

πŸ“ˆ Boston Scientific posted Q2 2026 revenue of USD 5.442 billion, up 7.5% year-over-year.

πŸ’° Adjusted EPS for the quarter reached USD 0.86, beating the USD 0.83 consensus estimate.

πŸ›‘οΈ A cybersecurity incident identified in late August disrupted manufacturing and order processing systems.

⚠️ The company has officially abandoned its previous guidance for Q3 and full-year 2026 earnings.

πŸ“… An updated outlook regarding the impact of the cyberattack is scheduled for release on October 28, 2026.

πŸ“‰ Citigroup lowered its price target from USD 50 to USD 48 due to operational concerns.

🏦 The stock trades at USD 42.55, significantly below its 52-week high of USD 105.65.

πŸ‘ Analyst consensus remains Moderate Buy with an average price target of USD 67.88.

Bullish Signals
  • Boston Scientific delivered strong Q2 2026 financial results with revenue growing 7.5% to USD 5.442 billion.
  • The company beat analyst expectations for adjusted EPS, reporting USD 0.86 versus a consensus of USD 0.83.
  • Operational resilience is evident as distribution centers and most manufacturing facilities resumed activity by September 8, 2026.
Risk Factors
  • A cybersecurity incident identified on August 25, 2026, disrupted manufacturing operations and customer shipments.
  • The company has officially abandoned its earlier third-quarter and full-year 2026 earnings forecasts due to the operational disruption.
  • Citigroup lowered its price target from USD 50 to USD 48 on October 5, 2026, reflecting concerns over the impact of the cyberattack.
Full Analysis
Boston Scientific reported Q2 2026 revenue of USD 5.442 billion, representing a 7.5% increase from the prior year, with adjusted EPS reaching USD 0.86 against a consensus estimate of USD 0.83. Despite this financial beat, the company faces significant operational headwinds following a cybersecurity incident identified on August 25, 2026, which disrupted manufacturing and customer shipments. Although distribution centers and most facilities resumed activity by early September, Reuters reported that Boston Scientific no longer expects to meet its earlier third-quarter and full-year 2026 forecasts. The company is scheduled to provide an updated outlook on October 28, 2026, which will serve as a critical checkpoint for investors to assess shipment recovery, revenue recapture, and the path toward its 2027 growth framework. Market sentiment remains mixed as Citigroup lowered its price target from USD 50 to USD 48 on October 5, citing the operational disruption, while maintaining a neutral rating. However, broader analyst consensus remains Moderate Buy with an average price target of USD 67.88, suggesting that the market views the current stock price of approximately USD 42.55 as undervalued relative to long-term potential despite near-term execution risks.